Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06054906 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 30, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2024 to Jun 30, 2025
    • Start date changed from estimate of Sep 25, 2023 to Oct 18, 2023
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Huashan Hospital
96 trials monitored
See 4 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) in resectable locally advanced gastric cancer.
Trial Details
NCT Number NCT06054906
Lead Sponsor Huashan Hospital
Conditions
(from sponsor)		 Gastric Cancer
Related terms Stomach Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov